The present economic analysis demonstrated that increased usage of calcium-free balanced crystalloid solution (BAL) in patients with systemic inflammatory response syndrome (SIRS) resulted in substantial cost savings for both the hospital and pharmacy in the US setting.

Savings were attributed to the reduction in key clinical complications such as sepsis, pneumonia, respiratory failure, and heart failure, which are significantly associated with crystalloid choice in SIRS patients. This is compelling considering the growing emphasis on healthcare cost containment with a focus on minimizing hospital adverse clinical outcomes.

Savings were observed outside of any additional reimbursement received for complications, and far outweighed the incremental fluid costs associated with increased BAL usage. Moreover, savings were evident across multiple scenarios, indicating potential economic benefits to hospitals of various sizes and varying adoption capability.